Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods
Hong-Mei Zhang, Xi-Yang Liu, Yu-Zhang Liu, Li-Na Liu, Quan-De Lin, Yong-Ping Song, Bai-Jun Fang Department of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People’s Republic...
Main Authors: | Zhang HM, Liu XY, Liu YZ, Liu LN, Lin QD, Song YP, Fang BJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-09-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/analysis-of-the-efficacy-and-safety-of-bortezomib-for-treating-newly-d-peer-reviewed-article-CMAR |
Similar Items
-
Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
by: Ye Z, et al.
Published: (2019-05-01) -
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01) -
Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01) -
Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
by: Wang H, et al.
Published: (2016-01-01) -
Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)